Screener
R&D at other companies
Segments
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues | $13,819 | $10,003 | $28,265 | $18,723 |
| Costs and expenses: | ||||
| Manufacture and supply | 4,017 | 4,561 | 7,486 | 8,213 |
| Research and development | 3,962 | 4,105 | 8,166 | 9,466 |
| Selling, general and administrative | 14,063 | 12,705 | 25,040 | 31,777 |
| Total costs and expenses | 22,042 | 21,371 | 40,692 | 49,456 |
| Loss from operations | (8,223) | (11,368) | (12,427) | (30,733) |
| Other income/(expenses): |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s R&D?
- Aquestive Therapeutics, Inc. (AQST) reported R&D of $3.96M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s R&D decreased by 3.5% year-over-year, from $4.11M to $3.96M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s R&D has grown at a 0.2% compound annual growth rate (CAGR), from $17.05M to $17.19M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Aquestive Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude